Trial Profile
Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5 [Benefici del paracalcitolo iniettabile sulla morbilita cardiaca indotta da insufficienza renale in soggetti con nefropatia cronica di stadio 5]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary)
- Indications Kidney disorders
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Registrational
- Acronyms PRIMO-II
- Sponsors Abbott Laboratories
- 22 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Feb 2009 New trial record